Advertisement


Betty Hamilton, MD: Research Highlights in GVHD

2025 Tandem Meetings

Advertisement

Betty Hamilton, MD, of Cleveland Clinic, outlines key data from a clinical session she co-chaired on graft-vs-host disease (GVHD), including the role of JAK inhibitors in the prevention of the condition and novel therapies for the management of acute GVHD.



Related Videos

Hematologic Malignancies
Supportive Care

Kristina Maas-Bauer, MD, on ROCK1/2 Inhibition and GVHD

Kristina Maas-Bauer, MD, of the University of Freiburg, discusses preclinical research on the role of ROCK1/2 in graft-vs-host disease (GVHD), which found an effect on myeloid cells, both in phenotype profile and migration capabilities. Additionally, she discusses the potential of combining ROCK1/2 inhibitors with ruxolitinib for refractory GVHD.

Advertisement

Advertisement




Advertisement